BioMarin Pharma (BMRN) Tops Q4 EPS by 37c ; Offers Guidance

BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.92, $0.37 better than the analyst estimate of $0.55. Revenue for the quarter came in at $747 million versus the consensus estimate of $711.42 million.

GUIDANCE:

BioMarin Pharma sees FY2025 EPS of $4.20-$4.40, versus the consensus of $4.16. BioMarin Pharma sees FY2025 revenue of $3.1-3.2 billion, versus the consensus of $3.1 billion.

For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.

You May Also Be Interested In

• Nucor projects Q3 2026 earnings above prior year, below estimates
• StrategX closes second tranche, raising $198,000 in private placement
• Allied Gold connects Kurmuk mine to Ethiopia's grid, feeds first ore